Harbor Health, a Texas-based primary care clinic group offering virtual and in-person care, common catalystwith participation from Alta Partners and 8VC.
This investment brings the company's total funding to more than $128 million.
This funding will support the growth of services and the delivery of specialty care, including the design of plans that patients and their care teams can co-create to support their care journey and available to Texas employers to reduce costs. It will be used for expansion.
“To maximize the impact of our innovations, we need to consolidate our efforts into one company as a vertically integrated ‘pay bidder’ – both payer and provider. ,” explains Dr. Clay Johnston, co-founder of Harbor Health. .
“With this new investment and our rapid growth, we have created a geographically dense model of care organized around integrated practice units and focused on the health of our members. , our innovative care model is proving to be working and bringing more people together collaboratively, no matter where they are.'' , Team-Based Care. ”
Peerlogic, an AI-enabled dental practice technology company, has secured $5.65 million in seed equity funding, which will be used to expand the company and services.
This round was led by AZ-VC, Cervin Ventures, In Revenue Capital, Revere Partners, and Singularity Capital participate.
The company provides an AI-powered conversation technology platform that helps dental practices communicate with customers and increase revenue and efficiency.
“This significant investment from a respected investor confirms our solid growth strategy and our unwavering commitment to delivering cutting-edge AI technology,” said Ryan, CEO and Founder of PeerLogic.・Mr. Miller said in a statement. “With this funding, we are poised to accelerate growth, introduce innovative products and strengthen our leadership in the dental industry.”
Clinical trial design company using AI Quant Health announced that it has added additional funds. Series A roundbringing total Series A funding to $17 million.
The Series A follow-on investment was contributed by CRO firm Accenture Ventures and additional investors.
The company offers an AI-powered clinical simulator that predicts individual responses to treatments during clinical trials and optimizes clinical trial design.
„Clinical trials are an expensive and uncertain process, and research and development costs for new drugs can exceed $1 billion,“ said Orr Inbar, co-founder and CEO of QuantHealth. mentioned in.
“QuantHealth has created a solution that uses AI to transform the way pharmaceutical companies approach clinical trials. We are able to seamlessly integrate data and cloud technology into the clinical trial process, saving pharmaceutical companies time. and cost savings, as well as „opportunities for success in drug development. Accenture's years of experience in this industry and leadership in data and AI will help us continue to expand our platform globally.“